Carbohydrate and domain architecture of an immature antibody glycoform exhibiting enhanced effector functions

J Mol Biol. 2009 Apr 17;387(5):1061-6. doi: 10.1016/j.jmb.2009.02.033. Epub 2009 Feb 21.

Abstract

Antibodies contain a conserved glycosylation site that has emerged as a target for the modulation of antibody effector functions. The crystal structure of a biosynthetic intermediate of human IgG1, bearing immature oligomannose-type glycans and reported to display increased antibody-dependent cellular cytotoxicity, demonstrates that glycan engineering can bias the Fc to an open conformation primed for receptor binding.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibody-Dependent Cell Cytotoxicity
  • Carbohydrate Sequence
  • Crystallography, X-Ray
  • Glycosylation
  • Humans
  • Immunoglobulin Fc Fragments / chemistry
  • Immunoglobulin Fc Fragments / genetics
  • Immunoglobulin Fc Fragments / metabolism
  • Immunoglobulin G / chemistry*
  • Immunoglobulin G / genetics
  • Immunoglobulin G / metabolism
  • In Vitro Techniques
  • Models, Molecular
  • Oligosaccharides / chemistry
  • Protein Structure, Tertiary
  • Recombinant Proteins / chemistry
  • Recombinant Proteins / genetics
  • Recombinant Proteins / metabolism
  • Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
  • Static Electricity

Substances

  • Immunoglobulin Fc Fragments
  • Immunoglobulin G
  • Oligosaccharides
  • Recombinant Proteins
  • oligomannoside

Associated data

  • PDB/2WAH